NCT04741997 2026-03-02
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Recruiting
Clinical Trials
22 trialsNCT07210632 2026-02-27
Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)
Vanderbilt-Ingram Cancer Center
Phase EARLY_PHASE1 Not yet recruiting
NCT05358938 2026-02-06
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT03543969 2026-02-05
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT02210117 2026-01-07
Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT05704933 2025-10-20
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Completed
NCT03463408 2025-08-11
Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma
University of Rochester
Phase EARLY_PHASE1 Active not recruiting
NCT04581382 2025-07-10
Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT03143270 2025-05-02
A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT03162731 2025-04-29
Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer
Thomas Jefferson University
Phase EARLY_PHASE1 Completed
NCT04134325 2025-04-16
Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT03311958 2025-04-06
Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance
Fox Chase Cancer Center
Phase EARLY_PHASE1 Completed
NCT05482451 2024-08-21
Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer
China Medical University Hospital
Phase EARLY_PHASE1 Active not recruiting
NCT03316274 2024-06-25
Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma
University of California, San Francisco
Phase EARLY_PHASE1 Completed
NCT03519308 2024-03-15
A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Terminated
NCT03812562 2024-02-21
Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection
Northwestern University
Phase EARLY_PHASE1 Terminated
NCT06204614 2024-01-12
Drug Screening Using IMD in Bladder Cancer
Brigham and Women's Hospital
Phase EARLY_PHASE1 Unknown
NCT03575598 2023-07-27
SNOW
University Health Network, Toronto
Phase EARLY_PHASE1 Completed
NCT03526185 2022-07-25
A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes
Yale University
Phase EARLY_PHASE1 Terminated
NCT04891718 2022-07-08
CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia
Presage Biosciences
Phase EARLY_PHASE1 Withdrawn
NCT04272333 2022-04-14
Intratumoral Microdosing of Motolimod in HNSCC
Presage Biosciences
Phase EARLY_PHASE1 Terminated
NCT04570683 2020-09-30
Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas
Bispebjerg Hospital
Phase EARLY_PHASE1 Unknown